William Blair Comments on Sight Sciences, Inc.’s Q1 2024 Earnings (NASDAQ:SGHT)

Sight Sciences, Inc. (NASDAQ:SGHT – Get Rating) – Equities research analysts at William Blair issued their Q1 2024 earnings per share (EPS) estimates for Sight Sciences in a report issued on Tuesday, March 14th. William Blair analyst M. Kaczor forecasts that the company will post earnings of ($0.33) per share for the quarter. The consensus estimate for Sight Sciences’ current full-year earnings is ($1.35) per share. William Blair also issued estimates for Sight Sciences’ Q2 2024 earnings at ($0.28) EPS.

A number of other equities analysts also recently issued reports on SGHT. Citigroup increased their target price on Sight Sciences from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Morgan Stanley boosted their price objective on Sight Sciences from $11.00 to $15.00 and gave the stock an “overweight” rating in a research note on Friday, January 6th. Finally, Stifel Nicolaus upgraded Sight Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $15.00 in a research note on Friday, January 6th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Sight Sciences Trading Up 1.4 %

NASDAQ:SGHT opened at $9.85 on Wednesday. The stock has a 50-day simple moving average of $11.60 and a 200-day simple moving average of $9.86. The stock has a market cap of $474.29 million, a P/E ratio of -5.47 and a beta of 1.31. Sight Sciences has a 1 year low of $5.35 and a 1 year high of $15.94. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.47 and a current ratio of 12.79.

Sight Sciences (NASDAQ:SGHT – Get Rating) last released its quarterly earnings data on Monday, March 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.07. Sight Sciences had a negative return on equity of 42.18% and a negative net margin of 130.24%. The company had revenue of $20.54 million for the quarter, compared to analyst estimates of $20.38 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share.

Institutional Trading of Sight Sciences

Hedge funds have recently modified their holdings of the stock. First Republic Investment Management Inc. acquired a new stake in Sight Sciences in the 2nd quarter valued at $4,961,000. JPMorgan Chase & Co. increased its position in Sight Sciences by 4,555.6% during the 4th quarter. JPMorgan Chase & Co. now owns 540,566 shares of the company’s stock worth $6,600,000 after purchasing an additional 528,955 shares in the last quarter. Vanguard Group Inc. increased its position in Sight Sciences by 92.9% in the 1st quarter. Vanguard Group Inc. now owns 1,082,725 shares of the company’s stock valued at $12,517,000 after acquiring an additional 521,412 shares during the period. BlackRock Inc. increased its position in Sight Sciences by 77.2% in the 1st quarter. BlackRock Inc. now owns 1,163,672 shares of the company’s stock valued at $13,453,000 after acquiring an additional 507,029 shares during the period. Finally, Jackson Square Partners LLC boosted its stake in shares of Sight Sciences by 43.4% in the 4th quarter. Jackson Square Partners LLC now owns 1,209,704 shares of the company’s stock valued at $14,770,000 after purchasing an additional 366,093 shares during the last quarter. 50.21% of the stock is owned by institutional investors.

Sight Sciences Company Profile

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.